These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 23839309)

  • 1. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
    Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
    Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
    Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
    J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
    Friedman J; Nottingham L; Duggal P; Pernas FG; Yan B; Yang XP; Chen Z; Van Waes C
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6568-78. PubMed ID: 18006756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
    Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
    Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.
    Ma Z; Yao G; Zhou B; Fan Y; Gao S; Feng X
    Mol Med Rep; 2012 Oct; 6(4):897-903. PubMed ID: 22825736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional kinomics identifies candidate therapeutic targets in head and neck cancer.
    Moser R; Xu C; Kao M; Annis J; Lerma LA; Schaupp CM; Gurley KE; Jang IS; Biktasova A; Yarbrough WG; Margolin AA; Grandori C; Kemp CJ; Méndez E
    Clin Cancer Res; 2014 Aug; 20(16):4274-88. PubMed ID: 25125259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
    Liu Y; Kwiatkowski DJ
    Mol Cancer Ther; 2015 Jan; 14(1):174-82. PubMed ID: 25349305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
    Bauer JA; Kumar B; Cordell KG; Prince ME; Tran HH; Wolf GT; Chepeha DB; Teknos TN; Wang S; Eisbruch A; Tsien CI; Urba SG; Worden FP; Lee J; Griffith KA; Taylor JM; D'Silva N; Wang SJ; Wolter KG; Henson B; Fisher SG; Carey TE; Bradford CR
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S106-8. PubMed ID: 17848273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H; Nishimura M; Oumi N; Kato M; Oishi T; Shimada M; Sato S; Naniwa J; Sato S; Kudoh A; Kigawa J; Harada T
    Int J Gynecol Cancer; 2014 Jan; 24(1):61-9. PubMed ID: 24362713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
    Landau HJ; McNeely SC; Nair JS; Comenzo RL; Asai T; Friedman H; Jhanwar SC; Nimer SD; Schwartz GK
    Mol Cancer Ther; 2012 Aug; 11(8):1781-8. PubMed ID: 22653969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
    BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
    Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
    Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
    Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
    Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
    Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
    Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death.
    Hsu WH; Zhao X; Zhu J; Kim IK; Rao G; McCutcheon J; Hsu ST; Teicher B; Kallakury B; Dowlati A; Zhang YW; Giaccone G
    J Thorac Oncol; 2019 Jun; 14(6):1032-1045. PubMed ID: 30771522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
    Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
    Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.